Evaluation of Florbetaben as a marker of amyloid plaque in patients with focal or AGES Disseminated Superficial hemosiderosis: comparison with patients with Alzheimer's disease patients and controls

Trial Profile

Evaluation of Florbetaben as a marker of amyloid plaque in patients with focal or AGES Disseminated Superficial hemosiderosis: comparison with patients with Alzheimer's disease patients and controls

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Florbetaben F18 (Primary)
  • Indications Cerebral amyloid angiopathy
  • Focus Diagnostic use
  • Acronyms FBB AAC
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 13 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top